WHAT YOU NEED TO KNOW
  • Researchers examined 22 pancreatic tumors from seven Black patients and 15 non-African American patients.
  • Tumors from Black patients showed different cancer cell patterns, more B cells and larger immune cell clusters.
  • No significant group differences emerged in the major genetic changes known to drive pancreatic cancer.
  • Researchers said larger, more diverse studies are needed before the findings can influence treatment or survival outcomes.

A University of Cincinnati study has uncovered differences in pancreatic tumors that may help explain why the disease affects some patients differently. Researchers said the findings could eventually support more personalized treatment approaches, although major questions remain unanswered.

The researchers examined 22 pancreatic tumors from patients of different racial backgrounds across the United States. The group included seven Black patients and 15 non-African American patients, and the findings were published in the journal Cancer Research.

Tumors from Black patients contained fewer of the most common pancreatic cancer cells and more cells showing a mixture of different characteristics. Some of those characteristics have previously been associated with drug resistance, but the study did not establish whether they influenced treatment outcomes.

The tumors from Black patients also contained more B cells, which are a type of immune cell, along with larger clusters of immune cells. Researchers identified signs that some B cells may suppress the body’s response to cancer, though the importance of those differences remains unclear.

Dr. Raymond Wadlow, a gastrointestinal medical oncologist at Inova Schar Cancer Institute in Virginia, was not involved in the research. He said immunotherapy, which is intended to help the immune system attack disease, has proved particularly difficult to use against pancreatic cancer.

“That's been very difficult to do in pancreatic cancer because the pancreatic tumor subverts the immune system so that it is fighting for it instead of for the host or the rest of the body,” Wadlow told Fox News Digital.

Despite the cellular and immune differences, researchers found no significant differences between the groups in the major genetic changes known to drive pancreatic cancer. According to the researchers, pancreatic cancer is approximately 20% more likely to develop in Black Americans than in non-African Americans.

Lead study author Nina Steele, Ph.D., an assistant professor in the University of Cincinnati’s College of Medicine, said the results highlight the importance of including patients from different backgrounds in cancer research. “This study shows that ignoring diverse ancestry in medical research leaves blind spots in the search for a cure,” she told Fox News Digital.

Do you read nutrition labels before buying packaged foods?

By completing the poll, you agree to receive emails from Being Healthy News, occasional offers from our partners and that you've read and agree to our privacy policy and legal statement.

Wadlow noted that pancreatic cancers can share major DNA mutations while differing considerably in how their cells behave. They may also differ in how those cells interact with nearby immune cells and surrounding tissue.

“Those differences may also vary across patient populations, such as between Black and non-Black patients,” Wadlow said. He added that the findings could be important for understanding pancreatic cancer disparities and eventually developing more individualized treatments.

Pancreatic cancer can vary from one tumor to another and even within the same tumor, according to Wadlow. “The cancer cell itself is only part of the story,” he said.

The immune cells and tissue surrounding a tumor may influence how it behaves and responds to treatment. Those factors could help explain why one treatment approach may not work for every patient.

However, researchers have not established how the intermediate tumor cells identified in the study affect survival. Steele said it also remains unknown whether those cells respond differently to standard chemotherapy.

The research team also needs to examine pancreatic tissue from people without cancer to better understand when the observed differences develop. Wadlow cautioned that race and genetic ancestry do not fully account for the environmental, socioeconomic and biological factors that could explain the findings.

Larger studies involving patients from diverse backgrounds are needed to determine whether the differences influence treatment outcomes or survival. “While intriguing, these findings are still a long way from changing patient care,” Wadlow said.

Wadlow encouraged patients with a new pancreatic cancer diagnosis to ask about hereditary genetic testing, which can identify inherited mutations that may also affect relatives. “If we find an inherited mutation, then family members can be tested,” he said.

Steele also called for clinical trials that represent the full range of patients affected by pancreatic cancer. “It is also a reminder for the medical system to ensure that clinical trials reflect the entire population at risk, in order to find treatments that can help all patients, not just some patients,” she said.

The research was funded in part by the National Cancer Institute. Its findings raise new questions about tumor biology and immune activity while emphasizing how much researchers still need to learn before the differences can guide patient care.